top of page


A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC.

Some patients have a tumor that is “resectable,” which means that it is able to be removed with surgery. For these cases, doctors have created the medicine called Cemiplimab, which can treat cancer by working with your immune system. This clinical trial will study how well the drug Cemiplimab works on resectable Hepatocellular carcinoma (HCC) and other cancers. Cemiplimab is a monoclonal antibody which is an immune therapy. The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing. Doctors will measure how well this treatment works on delaying potential surgery and how the immune system responds after taking this medicine.

For more information about the trial, click the link below:


Clinical Trial Site: Sinai

To see all available clinical trials click here.

Recent Posts

See All


A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064


Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot


A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors Antibodies are part of our body's defense system. They can specifically recognize damaging substances in the body, including tumor cell


bottom of page